Kearney releases 2027 beauty outlook report

Kearney forecasts beauty, health, and wellness will form a $937 billion global market growing at more than 5% annually; beauty products account for $430 billion, while services are growing faster at 7% versus products’ 6%. Services make up more than half of monthly beauty spend in four of five markets, and fragrance is the fastest-growing category at 10%. The report also identifies AI and trusted advocates as increasingly influential in product discovery and warns that brands’ use of similar AI tools could encourage category-wide sameness.

Analysis

The investable read-through is a change in value capture, not a simple expansion of beauty demand. Services can take more wallet share while capturing less profit per dollar than repeatable products: labor, utilization, clinician recruitment, and local capacity constrain scale. Treat service growth as a revenue signal, not proof of superior margins. Meanwhile, AI-led discovery risks transferring bargaining power to platforms and trusted creators; brands may pay more for acquisition while receiving less loyalty beyond the individual product. That makes customer ownership, repeat rates, and contribution margin more important than reach.

Contrarian view: the report’s consumer survey is directional, not evidence that spending or earnings are accelerating; it covers five markets and is based on stated behavior. The service opportunity may also be overstated by combining wellness, clinical care, and beauty into one market with different economics and regulation. Fragrance growth is attractive but could invite fast imitation and higher marketing costs. Over 1–3 months, look for company guidance or disclosed service utilization, repeat visits, and customer-acquisition costs before repricing the theme. Over 6–18 months, the key risk is that clinical demand outpaces provider capacity or faces tighter rules, while AI-driven product similarity erodes brand pricing power.

Key Decisions for Investors

• No immediate broad beauty-sector trade: this is a consulting outlook, not a verified earnings revision. Avoid treating the combined market size or consumer intentions as company-level revenue forecasts.
• Build a relative-value screen, rather than buying the theme outright: compare listed dermatology/aesthetic-service operators with product-led beauty companies on organic growth, site utilization, labor costs, repeat rates, and free-cash-flow conversion. Consider a long-service/short-product expression only if operating data confirms growth with durable margins.
• Within product beauty, favor evidence of repeat purchase and pricing resilience over broad brand portfolios. Track customer-acquisition costs and product-level retention; rising paid-social spend or weaker repeat rates would falsify the presumed benefit from advocacy and AI discovery.
• Catalysts to monitor over the next 1–3 months: earnings guidance, disclosed medspa/clinical utilization, platform-commerce economics, and regulatory changes affecting aesthetic procedures. Reassess if service growth is accompanied by falling utilization or margin pressure.